Patents by Inventor Nigel Liverton

Nigel Liverton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists
    Patent number: 7452893
    Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: November 18, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Wayne Thompson, Steven D. Young, Brian T. Phillips, Peter Munson, Willie Whitter, Nigel Liverton, Christine Dieckhaus, John Butcher, John A. McCauley, Charles J. McIntyre, Mark E. Layton, Philip E. Sanderson
  • N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
    Publication number: 20070149568
    Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMD NR2B antagonists useful for treating conditions such as, for example, Parkinson's disease, Alzheimer's disease, migraine, epilepsy and pain.
    Type: Application
    Filed: March 10, 2004
    Publication date: June 28, 2007
    Inventors: Nigel Liverton, Christopher Claiborne, David Claremon, John McCauley
  • Isoquinoline potassium channel inhibitors
    Publication number: 20070054892
    Abstract: The present invention relates to compounds of structural formula I: I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 22, 2004
    Publication date: March 8, 2007
    Inventors: Richard Isaacs, Christopher Dinsmore, B. Trotter, Nigel Liverton, Douglas Beshore, Nathan Kett, Charles McIntyre, Kausik Nanda, David Claremon
  • 4-Cycloakylaminopyrazolo pyrimidine nmda/nr2b antagonists
    Publication number: 20070037829
    Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.
    Type: Application
    Filed: August 11, 2004
    Publication date: February 15, 2007
    Applicant: MERCK & CO., INC.
    Inventors: Wayne Thompson, Steven Young, Brian Phillips, Peter Munson, Willie Whitter, Nigel Liverton, Christine Dieckhaus, John Butcher, John McCauley, Charles McIntyre, Mark Layton, Philip Sanderson
  • Isoquinolinone potassium channel inhibitors
    Publication number: 20070027177
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 17, 2004
    Publication date: February 1, 2007
    Inventors: B. Trotter, Christopher Claiborne, Gerald Ponticello, Charles McIntyre, Nigel Liverton, David Claremon
  • HCV NS3 protease inhibitors
    Publication number: 20070027071
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: July 12, 2006
    Publication date: February 1, 2007
    Inventors: M. Holloway, Nigel Liverton, Steven Ludmerer, John McCauley, David Olsen, Michael Rudd, Joseph Vacca, Charles McIntyre
  • 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
    Publication number: 20060160853
    Abstract: 2-[(4-Benzyl)-1-piperidinyl)-methyl]benzimidazole-5-ol derivatives are NMDA NR2B receptor antagonists useful in the treatment of pain and other NMDA mediated diseases.
    Type: Application
    Filed: November 18, 2003
    Publication date: July 20, 2006
    Inventors: John McCauley, David Claremon, Nigel Liverton
  • 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists
    Publication number: 20050054658
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.
    Type: Application
    Filed: August 12, 2004
    Publication date: March 10, 2005
    Inventors: Wayne Thompson, Steven Young, Brian Phillips, Peter Munson, Willie Whitter, Nigel Liverton, Christine Dieckhaus, John Butcher, John McCauley, Charles McIntyre, Mark Layton, Philip Sanderson
  • Carbocyclic potassium channel inhibitors
    Patent number: 6632836
    Abstract: The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 14, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Jennifer Chee, Maria L. Garcia, Gregory J. Kaczorowski, Frank Kayser, Andrew Kotliar, Chou Juitsai Liu, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht, William A. Schmalhofer, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Heterocyclic potassium channel inhibitors
    Patent number: 6303637
    Abstract: The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 16, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Andrew Kotliar, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Benzamide potassium channel inhibitors
    Patent number: 6194458
    Abstract: This invention relates to benzamide potassium channel inhibitors of general structural Formula I. The compounds of this invention are useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and related afflictions, diseases and illnesses, and cardiac arrhythmias. Also within the scope of this invention are pharmaceutical formulations comprising a compound of Formula I and a pharmaceutical carrier, as well as pharmaceutical formulations comprising a compound of Formula I, one or more immunosuppressive compounds and a pharmaceutical carrier.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: February 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Frank Kayser, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Fibrinogen receptor antagonists
    Patent number: 5821241
    Abstract: Compounds of the invention have the formula ##STR1## The compounds have fibrinogen receptor antagonist activity.
    Type: Grant
    Filed: August 1, 1995
    Date of Patent: October 13, 1998
    Assignee: Merck & Co., Inc.
    Inventors: David Alan Claremon, John J. Baldwin, Nigel Liverton, Ben Askew
  • N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo?B!?1,4!diazepi n-3yl)-acetamides
    Patent number: 5726171
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: March 13, 1996
    Date of Patent: March 10, 1998
    Inventors: David A. Claremon, Nigel Liverton, Garry R. Smith, Harold G. Selnick
  • N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides
    Patent number: 5700797
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 23, 1997
    Assignee: Merck & Co, Inc.
    Inventors: David A. Claremon, Nigel Liverton, Harold G. Selnick
  • 3-acylaminobenzazepines
    Patent number: 5696111
    Abstract: This invention is concerned with novel compounds represented by structural formula I and II. ##STR1## which are antiarrhythmic agents.
    Type: Grant
    Filed: May 16, 1996
    Date of Patent: December 9, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Nigel Liverton, Harold G. Selnick
  • N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides
    Patent number: 5691332
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: August 19, 1996
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Roger M. Freidinger, Nigel Liverton, Harold G. Selnick, Garry R. Smith
  • N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides
    Patent number: 5691331
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Roger M. Freidinger, Nigel Liverton, Harold G. Selnick, Garry R. Smith
  • Benzodiazepines
    Patent number: 5679672
    Abstract: Compounds of structures (I) and (Ia) are Class III antiarrhythmic agents ##STR1##
    Type: Grant
    Filed: May 14, 1996
    Date of Patent: October 21, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Nigel Liverton, David C. Remy, Harold G. Selnick
  • 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzo diazepines
    Patent number: 5658901
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## where X and Y are independently hydrogen, chloro, fluoro, bromo, iodo, or trifluoromethyl and n is 0, 1 or 2;R is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy; andthe racemates, mixtures of enantiomers, individual diastereomers or individual enantiomers with all isomeric forms and pharmaceutically acceptable salts, hydrates or crystal forms thereof, which are antiarrhythmic agents.
    Type: Grant
    Filed: August 17, 1995
    Date of Patent: August 19, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Nigel Liverton, Harold G. Selnick
  • N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines
    Patent number: 5633251
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## where R.sup.1 is ##STR2## X and Y are independently hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl;n is 0, 1 or 2; andR.sup.2 is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy;as the racemates, mixtures of enantiomers, individual diastereomers or individual enantiomers, and pharmaceutically acceptable crystal forms, salts, or hydrates thereof.
    Type: Grant
    Filed: August 17, 1995
    Date of Patent: May 27, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Nigel Liverton, Harold G. Selnick